Flatiron Well being, which has constructed up an oncology-focused EHR community and a de-identified database with greater than 4 million affected person information, just lately introduced a milestone of over 1,000 analysis publications utilizing its EHR-derived real-world knowledge. Neal Meropol, M.D., the corporate’s vp of analysis oncology, just lately spoke with Healthcare Innovation concerning the growth of the sorts of analysis being executed with its knowledge.
Based in 2012, Flatiron is an unbiased affiliate of the Roche Group. It collaborates with companions in tutorial establishments, coverage teams, regulators, and biopharmaceutical firms.
A medical oncologist, medical investigator, and outcomes researcher, Meropol oversees Flatiron’s medical groups supporting retrospective and potential proof era.
Healthcare Innovation: At Healthcare Innovation, we deal with writing concerning the healthcare supplier aspect and never a lot about life science firms or drug growth. However clearly the 2 worlds are linked collectively, and Flatiron’s work is among the locations the place that occurs. You’ve got been at Flatiron for seven years. What are a few of the important modifications you’ve got seen by way of the corporate’s capabilities?
Meropol: In quite a lot of methods, it has been exceptional, however all inside the context of a constant mission, which has been to enhance and lengthen lives by studying from the expertise of each particular person with most cancers. The way in which we do that has largely remained unchanged over this time, and that is by offering software program and companies to training oncologists, the place we’re an EHR vendor, but in addition by curating knowledge largely derived from digital well being information that is collected throughout routine care to realize insights that assist handle care high quality and coverage, and that assist speed up drug growth and contribute to a studying healthcare system.
HCI: So what has modified over the previous 5 years or so?
Meropol: After we first began, our knowledge had been mostly used for market monitoring — how are new therapies being adopted? So the shoppers, in a method, had been industrial arms in biopharma. However we have advanced to have a much wider scope of analysis areas that our knowledge at the moment are utilized to. That features academia, authorities, NCI and regulators, nonprofits just like the American Most cancers Society and Pals of Most cancers Analysis. Having a broader array of customers of Flatiron real-world knowledge opens up avenues to all various kinds of of functions. Additionally, we’re now now not simply depending on the information within the digital well being document; we now have linkages to different exterior sources of information, like mortality databases, claims knowledge, digital photos, genomic knowledge. That actually opened the door to numerous various kinds of insights that we’re in a position to glean.
HCI: Does broadening out the sorts of analysis embody issues like well being fairness, at how persons are receiving care in numerous various kinds of settings?
Meropol: Precisely. The functions of our knowledge at this time not solely embody understanding adoption of recent therapies, but in addition understanding the real-world outcomes related to completely different patterns of care, with the ability to carry out comparative effectiveness, to know variations in approaches which may not be amenable to doing a potential medical trial.
We have executed work with what are known as pure experiments — wanting on the impression of drug shortages on healthcare supply and the outcomes of sufferers, and likewise nationwide insurance policies — for instance, growth of Medicaid and the way that impacts most cancers care. We measure high quality with Flatiron knowledge, how persons are utilizing biomarker testing, and whether or not sufferers are receiving care directed by biomarkers, and the way sufferers are being handled on the finish of life.
We have checked out many alternative areas of well being fairness, together with how rapidly sufferers provoke care, together with whether or not adoption of recent improvements is equal throughout completely different teams, whether or not the place you obtain care, whether or not it is an educational setting or group setting, impacts the care you obtain. The info are simply very wealthy by way of what is feasible.
HCI: Has the variety of oncology practices or tutorial medical facilities utilizing Flatiron’s OncoEMR or its different instruments continued to develop? And does the OncoEMR proceed to evolve with new options?
Meropol: Our footprint in group oncology and in academia continues to develop. By way of new options in OncoEMR, one thing that is actually notable is we now have over the previous a number of years developed resolution assist instruments. We’ve got an utility known as Flatiron Help, which helps information the suitable number of remedy based mostly on affected person traits, and this has been quickly adopted by our OncoEMR practices in an effort for the customers to enhance their high quality of care and streamline their resolution making.
HCI: Normally, we hear from tutorial medical facilities that creating and updating medical resolution assist guidelines is a fancy governance process. So is that one thing that it’s important to get enter from the community on?
Meropol: Two issues: One side is that out of the field, the Flatiron Help resolution is constructed on Nationwide Complete Most cancers Community medical follow tips. The second characteristic is that it is extremely customizable, so practices can select to customise the suggestions of Flatiron Help based mostly on their very own follow preferences.
HCI: What about including these AI scribe instruments to the EHR as nicely? Is that one thing Flatiron is engaged on?
Meropol: Sure, we have facilitated the testing of ambient AI for practices that need to go in that route, completely.
Additionally, one of many new areas which is absolutely important is that with the intention to leverage knowledge on the entire 4 million most cancers sufferers we comply with, we now have to seek out extra environment friendly methods to curate unstructured data, and we’re now routinely making use of machine studying and synthetic intelligence to help with curation the place the efficiency is high-quality, in order that we are able to develop the variety of sufferers that we’re in a position to have significant details about.
HCI: Might the ambient AI instrument change into good sufficient to determine what to place within the structured knowledge and what to place within the narrative?
Meropol: There’s quite a lot of dialogue occurring about what the digital well being document of the longer term will appear like. Traditionally digital well being information weren’t constructed for analysis, but when there are instruments that allow higher seize of data on the level of care in structured or usable format or functions that embody medical care billing, but in addition analysis functions, that might be good for everybody and really enabling by way of advancing the standard of most cancers care. So I believe all people is wanting in direction of a future the place that turns into extra potential, the place that turns into a actuality, however it’s not going to occur in a single day, as a result of EHR distributors like Flatiron are actually targeted on workflows and making certain that we’re serving to clinicians present probably the most environment friendly and high-quality care potential. And there is at all times a danger that implementation of recent applied sciences causes elevated clicks on the pc, and leads to extra burnout and has unintended penalties.
HCI: Are the shoppers who’re working in group oncology practices completely different from the individuals working within the tutorial medical facilities so far as the toolsets they need or want?
Meropol: The widespread drivers in group oncology settings and tutorial settings are that they’re attempting to supply the best high quality care to sufferers, however a serious driver for clinicians in an educational setting is skilled development. They is likely to be extra serious about collaborating in analysis and publishing outcomes, however I ought to be aware that Flatiron’s group oncology community has many practices in it that conduct medical trials analysis and are closely motivated to take action. So the incentives and the needs to have the ability to present innovative care within the type of medical trials exists each in the neighborhood and within the tutorial heart. And one of many issues that that we have actually constructed out over the previous a number of years is the supply of software program and companies to group oncologists to raised allow them to participate in medical trials. That features serving to with medical trial recruitment affected person matching, but in addition with the switch of information from the digital well being document to review databases. So we now have a instrument known as Scientific Pipe that could be a knowledge switch instrument for medical trials, which reduces website burden and permits extra websites to take part in additional research than they may in any other case have been in a position to do.
HCI: I do not forget that there was an announcement of a Flatiron partnership with the Affiliation of Most cancers Care Facilities to work on broadening entry to that instrument.
Meropol: Group oncologists, in actual fact, are sometimes very serious about constructing out their medical analysis capabilities, however the investments in medical analysis in an educational heart and in the neighborhood follow could also be very completely different. What we’re attempting to do is assist assist the infrastructure of conducting analysis in routine care settings. So we’re attempting to align medical research with medical care, and in doing so, make it extra of a routine method to how sufferers are cared for.
HCI: Do you need to speak a bit about your medical trial community?
Meropol: On the highest stage, we notice that knowledge collected in routine care — what we take into account retrospective real-world knowledge — can’t reply all questions in oncology. There are specific analysis questions, sure proof wants that require the gathering of what we name deliberately collected data that goes past what’s routinely collected, whether or not that’s measuring tumor dimensions, or whether or not it’s ensuring that the affected person’s useful standing is precisely documented earlier than care is initiated. So Flatiron has constructed out a enterprise the place we are going to assist medical trials’ potential knowledge assortment, ideally for research which might be pragmatically designed and extremely aligned with routine care.
So we’re constructing out the capabilities for conducting medical research inside the group setting. That features working with sponsors on the design of research, utilizing Flatiron knowledge to assist inform research design, supporting affected person identification for research, after which supporting the information assortment that we have talked about. We imagine that we now have a chance to lower the complexity of medical trials that exist at this time by pragmatic research design, but in addition pragmatic operational design that can broaden accessibility to medical trials for most cancers sufferers.